Feminizing HRT: Estradiol Valerate + Progesterone
Representative feminizing HRT with injectable estradiol valerate and oral progesterone.
Model levels over time
% of sampled peakModel details: Estradiol Valerate · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Approximate Oriowo human IM peak; legacy 84 h half-life remains an assumption, not proven by the label. The retained 84 h slower timescale is an assumption.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 84 hours
- Absorption half-life assumed
- 16.38573 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 48 h source-scoped peak time; absorption half-life 16.385732568003874 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Do not adopt the commonly repeated 667 pg/mL total peak as an exogenous per-dose peak without baseline handling.
- Oral estradiol valerate and IM valerate are different routes.
- Oriowo et al 1980: three estradiol esters
Single 5 mg IM in 1 m L arachis oil; cypionate peakabout 4 days, valerateabout 2 days; groups 10/9/10 women.
- Delestrogen label
IM estradiol-valerate oil product; does not provide a standalone baseline-corrected fitted curve.
estradiol-valerate-relative-timing-2026-10 · version 1
Model details: Progesterone (Oral) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 22.78 h/1.5 h from a repeated-dose capsule study cannot establish universal per-dose kinetics. The retained 22.78 h slower timescale is an assumption.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 22.78 hours
- Absorption half-life assumed
- 5.695 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (5.695 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Food, soft vs hard capsule, first-pass metabolites and assay cross-reactivity materially affect measured exposure.
- Baseline progesterone and serum/plasma assay must be specified; no invented 10% F.
- Wang et al 2019: hard and soft micronized progesterone
Utrogestan oral 169.53 and vaginal 12.30 are steady-state observations after 200 mg twice daily 10 days; different products/routes had different PK. Abstract concentration units conflict with tables, so use the tables and original assay context.
- Prometrium label
100 mg daily for five doses: mean Cmax 17.3 ng/mL; this is not a single-dose study.
progesterone-oral-relative-timing-2026-10 · version 1
Different scales · each curve is normalized to its own peak. Compare timing and shape, not concentration or potency.
| Date | Progesterone (Oral) · Relative timing (% of sampled peak) | Estradiol Valerate · Relative timing (% of sampled peak) |
|---|---|---|
| W1 | 0 % of sampled peak | 0 % of sampled peak |
| W2 | 0 % of sampled peak | 44.395 % of sampled peak |
| W4 | 0 % of sampled peak | 54.1617 % of sampled peak |
| W6 | 91.2941 % of sampled peak | 85.4831 % of sampled peak |
| W7 | 99.785 % of sampled peak | 71.6333 % of sampled peak |
| W8 | 99.6334 % of sampled peak | 58.3564 % of sampled peak |
| W9 | 94.1549 % of sampled peak | 46.1479 % of sampled peak |
| W11 | 93.1424 % of sampled peak | 84.9786 % of sampled peak |
| W12 | 83.5321 % of sampled peak | 99.4866 % of sampled peak |
| W13 | 78.3217 % of sampled peak | 88.9229 % of sampled peak |
| W14 | 92.4267 % of sampled peak | 74.0872 % of sampled peak |
| W15 | 98.979 % of sampled peak | 60.084 % of sampled peak |
| W16 | 99.8065 % of sampled peak | 49.0838 % of sampled peak |
The chart uses a bounded time grid. Long horizons can miss brief peaks between samples; shorten the horizon to inspect more detail. Chart peaks are sampled values.
Protocol summary
Feminizing HRT: Estradiol Valerate + Progesterone · 16 weeks starting Oct 30, 26
- Estradiol Valerate — 5.00 mg Every 7 days, weeks 0–16
- Progesterone (Oral) — 100.0 mg Every day, weeks 5–16
Protocol overview
- Category
- trt hrt
- Duration
- 16 weeks
- Compounds
- 2
- Tags
- hrt, estradiol, progesterone, female
Compounds in this protocol
- Estradiol Valerate — 5 mg, every-7-days
- Progesterone (Oral) — 100 mg, every-day (weeks 5-16)
How to read this protocol
The chart shows available model curves over the 16-week example. Rows whose model is unavailable are retained for context but produce no curve. Read each model’s details for what its line represents; a plotted level does not predict treatment effects or establish a suitable dose.
The peak/trough explorer examines one complete model interval. The single-dose decline explorer is a separate one-dose scenario; it does not calculate this protocol's washout or a safe treatment-change date. Read the recovery reference for PCT evidence and its limits.
Educational only. Not medical advice. These examples do not predict individual blood levels.